Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant965 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02966691 | Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors(VISIOCYT 1) | completed | N/A | 1,360 | VitadxOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03689478 | Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT(I-HIVEC) | completed | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Jan 3, 2022 |
| clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT05168436 | A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | completed | — | 105 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 23, 2021 | clinicaltrials |
| NCT03294304 | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | completed | Phase 2 | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04342286 | To Establish a Reproducible Organoid Culture Model With Human Kidney Cancer | completed | — | 20 | Chinese University of Hong KongOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT03916458 | REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA(ATILA) | completed | — | 62 | PfizerINDUSTRY | 1 | Dec 13, 2021 | clinicaltrials |
| NCT02228954 | IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)(IMPACT-RCC) | completed | — | 40 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01472081 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | completed | Phase 1 | 194 | Bristol-Myers SquibbINDUSTRY | 2 | Dec 2, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04353765 | Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors(US NIS Cabo) | completed | — | 247 | IpsenINDUSTRY | 1 | Nov 17, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03548688 | Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer:(IDENTIFY) | completed | — | 11,059 | British Urology Researchers in Surgical TrainingOTHER | 1 | Nov 11, 2021 | clinicaltrials |
| NCT05113134 | Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen(STTELS) | completed | N/A | 38 | Seoul National University Bundang HospitalOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT01358721 | Phase I Biomarker Study (BMS-936558) | completed | Phase 1 | 119 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 28, 2021 | clinicaltrials |
| NCT01738815 | Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer | completed | Early Phase 1 | 43 | State University of New York - Upstate Medical UniversityOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT05089006 | Cost-effectivness of Robot-assisted Surgery Compared to Open Surgery for Partial Nephrectomy in Context of Renal Tumor(écoREIN) | completed | — | 400 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 22, 2021 | clinicaltrials |
| NCT03273751 | The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy | completed | N/A | 86 | Seoul National University HospitalOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04190641 | Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder | completed | N/A | 4 | Ambu A/SINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
| NCT03091764 | Evaluation of a Patient-Reported Symptom Index for NMIBC | completed | — | 498 | University of SydneyOTHER | 5 | Oct 13, 2021 | clinicaltrials |
| NCT01776138 | Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer(PORCH) | completed | — | 103 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04900259 | The Effect of the COVID-19 Pandemic on Primary Bladder Cancer Presentations | completed | — | 183 | Ankara Training and Research HospitalOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03900364 | a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy | completed | N/A | 30 | Salzburger LandesklinikenOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT05042089 | Predictive Imaging Features in Renal Cell Carcinoma | completed | — | 92 | Ankara Yildirim Beyazıt UniversityOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT04377113 | Cellular Immunity and Renal Cell Cancer | completed | — | 60 | Clinical Hospital Center RijekaOTHER | 1 | Sep 21, 2021 | clinicaltrials |
| NCT01392183 | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03525834 | Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. | completed | Phase 4 | 40 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT02335827 | Irreversible Electroporation(IRE) For Unresectable Renal Tumors(IRE) | completed | N/A | 15 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430623 | Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02430779 | Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms(IRE) | completed | N/A | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT02655822 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | completed | Phase 1 | 502 | Corvus Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 30, 2021 | clinicaltrials |
| NCT03748901 | PD-L1 Expression in Japanese Renal Cell Carcinoma Patients | completed | — | 830 | Chugai PharmaceuticalINDUSTRY | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04256161 | Measurements of Sexual Steroids' Concentrations in Prostatic Tissue(Pré-HORM) | completed | — | 24 | Hopital FochOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04496089 | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC(ZIRDAC-JP) | completed | Phase 1 | 6 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05015179 | Mixed Reality Technology in Laparoscopic Partial Nephrectomy | completed | N/A | 47 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Jan 6, 2022source: clinicaltrials